SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Far below the surface, where light no longer reaches and noise collapses into silence, the Sperm Whale endures.  It does not rely on speed or spectacle. It survives through mass, intelligence, and absolute awareness of its surroundings.  This project is shaped by the same principle — strength formed under pressure, movement guided by understanding, and conviction built where others cannot remain.  While the surface reacts, the deep decides.

The Sperm Whale

SPERMWHALE is trending as community members aggressively debate its potential for massive gains versus risks of a rug pull, with many investors actively rotating profits into competing projects like MAULCOIN. The conversation is dominated by high-energy shilling and speculation about whether the token can shed more zeros or if it is merely another volatile pump-and-dump scheme.

eBay, Inc. is a commerce company, whose platforms include an online marketplace and its localized counterparts, including off-platform businesses in South Korea, Japan, and Turkey, as well as eBay’s suite of mobile apps. It offers a platform for various product categories, including parts and accessories, collectibles, fashion, electronics, and home & garden. eBay generates revenue mainly through fees from sales, payment processing, and advertising. The company was founded by Pierre Morad Omidyar in September 1995 and is headquartered in San Jose, CA.

EBay Inc.

eBay Inc

eBay is trending following a media report that GameStop is building a stake in the company as part of a potential takeover strategy, fueling speculation about a high-stakes e-commerce merger. Community sentiment is deeply divided, with many traders expressing skepticism about the financial feasibility of such a deal while others debate the potential strategic value of integrating collectibles and retail operations.

Dumb SEND IT

Dumb SEND IT ($DSIT) is gaining momentum as the developer actively engages the community with daily airdrops and plans for a dedicated website, fueling sentiment that the current low market cap offers an early entry point. Community members are actively debating the project's resilience following initial volatility, with many highlighting locked liquidity and the anticipation of official chart integration as key catalysts for potential growth.

Terra is a decentralized financial payment network that rebuilds the traditional payment stack on the blockchain. Luna is the reserve currency of the Terra platform. It has three core functions: i) mine Terra transactions through staking, ii) ensure the price stability of Terra stablecoins and iii) provide incentives for the platform’s blockchain validators.

Terra Luna Classic

Terra Luna Classic is experiencing significant community attention and speculative interest as traders anticipate a major supply reduction driven by upcoming burn events. The discussion centers on long-term conviction, with many participants debating the potential for a price recovery and debating the merits of supporting active on-chain projects to foster ecosystem growth.

Leonardo DRS, Inc. engages in the provision of defense products and technologies. It develops and manufactures defense products for the U.S. military, intelligence agencies and allies around the world. Its broad technology portfolio focuses on advanced sensing, network computing, force protection, and electrical power and propulsion, as well as a range of key defense priorities. The company operates through the Advanced Sensors and Computing and Integrated Mission Systems segments. The Advanced Sensors and Computing segment have been aligned to push towards a more autonomous future. It consists of six business units, which include Airborne & Intelligence Systems, Daylight Solutions, DRS RADA Technologies, Electro-Optical & Infrared Systems, Land Electronics, and Naval Electronics. The Integrated Mission Systems segment consists of both a ground vehicle integrator and naval power and propulsion system provider. The company was founded by Leonard Newman and David E. Gross in 1969 and is headquartered in Arlington, VA.

Leonardo DRS Inc.

Leonardo DRS is gaining momentum as investors eye its strategic role in modern defense, particularly regarding missile defense systems and critical hardware for major naval programs. The community is actively discussing its inclusion in indices, potential contract expansions, and the company's vital position within the broader defense electronics supply chain.

The Mullen Army Token originated from a dedicated community of retail investors who faced challenges in the traditional stock market. We united to create a cryptocurrency that embodies our principles and aspirations for a fair financial system.     We provide a platform for retail investors to engage in a transparent and fair financial market. Our efforts include grassroots marketing, community engagement, and educational content to empower our investors.

MullenArmy

The MULN symbol is generating significant activity on social forums, with many users debating its transition from a struggling EV stock to a speculative crypto project, while community members aggressively promote various low-cap meme coins using the ticker as a rallying point. Investors remain deeply divided, with one side highlighting the potential for volatile price swings often associated with these meme-driven plays, while skeptical participants warn of historical patterns of dilution and recurring scams.

Frequency Electronics, Inc. engages in the design, development, and manufacture of precision time and frequency generation technology. It operates through the FEI-NY and FEI-Zyfer business segments. The FEI-NY segment provides precision time, frequency generation, and synchronization products and subsystems that are found on-board satellites, in ground-based communication stations, and imbedded in moving platforms. The FEI-Zyfer segment designs, develops, and manufactures products for precision time and frequency generation and synchronization, primarily incorporating GPS technology. The company was founded by Martin B. Bloch on August 25, 1961 and is headquartered in Uniondale, NY.

Frequency Electronics, Inc.

Frequency Electronics is seeing significant investor attention driven by a record-high funded backlog and a series of strategic contracts in satellite and quantum sensing technologies. The community is actively discussing the stock's potential for long-term growth as it pivots to next-generation defense applications while maintaining a debt-free balance sheet.

Daddy Darth Vader

PayPal USD is designed to contribute to the opportunity stablecoins offer for payments and is 100% backed by U.S. dollar deposits, short-term U.S Treasuries and similar cash equivalents. PayPal USD is redeemable 1:1 for U.S. dollars and is issued by Paxos Trust Company.

PayPal USD

PayPal USD is generating significant attention as the community weighs its cross-border expansion and integration into diverse blockchain ecosystems against ongoing legislative debates surrounding stablecoin regulation. Investors are actively discussing the potential impact of federal oversight on the stablecoin market while tracking its adoption rates across various decentralized finance platforms.

Advanced Biomed, Inc. operates as a holding company with interests in developing biochip technologies. It engages in the research & development of microfluidic biochip technologies and provides tumor diagnosis and treatment technology applications. The company was founded by Yi Lu and Steven I-Fang Cheng in 2014 and is headquartered in Tainan, Taiwan.

Advanced Biomed Inc

Advanced Biomed is experiencing significant volatility and trading volume as market participants debate its potential as a low-float momentum play following recent share purchase agreements. While some traders are focused on the stock's parabolic upside and thin float as catalysts for a squeeze, others are expressing caution regarding potential dilution risks and the historical trend of sell-offs following similar price spikes.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Kazia Therapeutics Strengthens Scientific Leadership with Appointment of Dr. Sudha Rao as Chief Scientific Officer to Lead Next-Generation Oncology Platform

Kazia Therapeutics Strengthens Scientific Leadership with Appointment of Dr. Sudha Rao as Chief Scientific Officer to Lead Next-Generation Oncology Platform Kazia Therapeutics Strengthens Scientific...

Kazia Therapeutics Expands Oncology Platform with First-in-Class SETDB1 Inhibitor Drug Development Platform

Kazia Therapeutics Expands Oncology Platform with First-in-Class SETDB1 Inhibitor Drug Development Platform Kazia Therapeutics Expands Oncology Platform with First-in-Class SETDB1 Inhibitor Drug...

<ul class="summary-bullets"><li>Kazia stated that in murine triple-negative breast cancer preclinical models, NDL2 reduced primary tumor volume by 49% as monotherapy.</li><li>In combination with the anti-PD-1 therapy, the treatment reduced the volume of the primary tumor by 73%.</li><li>In patients with lung metastases, Kazia stated that NDL2, combined with anti-PD-1 therapy, reduced the primary tumor’s volume by 50%.</li></ul>Kazia Therapeutics Inc.’s (KZIA) shares rose more than 6% in Friday’s pre-market trade after the company announced new preclinical and translational data for NDL2, a protein degrader.The Sydney, Australia-based oncology-focused pharmaceutical company stated that across multiple preclinical models and patient-derived samples, NDL2 demonstrated reversal of immune exhaustion, suppression of metastatic biology, and enhanced anti-tumor activity. This includes the combination of NDL2 with anti-PD-1 therapy, which uses monoclonal bodies such as nivolumab or pembrolizumab to block the PD-1 protein on T-cells.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/KZIA">Kazia Therapeutics</a> was in the ‘bullish’ territory at the time of writing, while message volume was at ‘high’ levels.<h2 class="st-heading-2">Highlights Of New NDL2 Data</h2>Kazia stated that in murine triple-negative breast cancer (TNBC) preclinical models, NDL2 reduced primary tumor volume by 49% as monotherapy. In combination with the anti-PD-1 therapy, the treatment reduced the volume of the primary tumor by 73%.In patients with lung metastases, Kazia stated that NDL2, combined with anti-PD-1 therapy, reduced the primary tumor’s volume by 50%.The company added that no toxicity or hemolysis was observed, while noting that the immune checkpoint function at the cell surface was preserved, and the plasma stability was favorable.<h2 class="st-heading-2">What Is NDL2 Aimed At?</h2>Kazia is currently developing the NDL2 protein degrader to selectively eliminate nuclear PD-L1 (Programmed Death-Ligand 1).PD-L1 is a protein found on the surface of many cancer cells as well as some normal cells. The protein helps these cells evade the immune system.<a href="https://stocktwits.com/symbol/KZIA">KZIA stock</a> is down 6% year-to-date and 12% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sofi-stock-rises-after-sofi-technologies-reports-1b-quarterly-revenue-first-time/cmySKHPR4ST">SOFI Stock Rises Pre-Market After SoFi Technologies Reports $1B Quarterly Revenue For The First Time</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a trending stock chart.

KZIA Stock Is Rising Today — What Does Its Data For Nuclear PD-L1 Degrader Show?

Kazia stated that across multiple preclinical models and patient-derived samples, NDL2 demonstrated reversal of immune exhaustion, suppression of metastatic biology, and enhanced anti-tumor activity.

Equity

Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2)

Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2) Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear...

Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer

Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer Kazia Therapeutics Reports...

Kazia Therapeutics to Participate in J.P. Morgan Healthcare Conference Week; Clinical and Translational Update Anticipated Before Month-End

Kazia Therapeutics to Participate in J.P. Morgan Healthcare Conference Week; Clinical and Translational Update Anticipated Before Month-End Kazia Therapeutics to Participate in J.P. Morgan Healthcare...

Is the Market Bullish or Bearish on Kazia Therapeutics Ltd?

Kazia Therapeutics Regains Full Nasdaq Listing Compliance

Kazia Therapeutics Regains Full Nasdaq Listing Compliance Kazia Therapeutics Regains Full Nasdaq Listing Compliance PR Newswire SYDNEY, Dec. 22, 2025 Restoration of Nasdaq compliance follows $50...

Kazia Therapeutics Highlights New Clinical and Translational Findings Demonstrating Paxalisib's Ability to Reinvigorate Anti-Tumor Immunity Across Multiple Advanced Breast Cancer Populations including TNBC and HER2+

Kazia Therapeutics Highlights New Clinical and Translational Findings Demonstrating Paxalisib's Ability to Reinvigorate Anti-Tumor Immunity Across Multiple Advanced Breast Cancer Populations...

What's Going On With Cancer Firm Kazia Therapeutics

Kazia announced a private placement of $50 million in equity securities. Proceeds will fund clinical development and extend cash runway.read more...

Kazia Therapeutics Ltd. is an oncology-focused biotechnology company, which engages in the business of pharmaceutical drug development. It focuses on its Paxalisib program, which is designed to treat brain cancer. The company was founded by Graham Edmund Kelly in March 1994 and is headquartered in Sydney, Australia.

Current Price	$13.39
Prev Close	$13.64
Open	$13.57
Dividend Yield	0.00%
50-Day Moving Average	$8.92
Beta	1.31
Avg. Volume	291,525.05
PE Ratio	-1.96

52-Week High	$17.40
52-Week Low	$3.05
Market Capitalization	$151.79M
EPS (Annual)	-$12.23
Price to Book	4.90
Revenue Per Employee	N/A

KZIA
Kazia Therapeutics

Feed

News

Sentiment

Fundamentals

Info

Latest KZIA News

KZIAKazia Therapeutics